This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

Appraisal process

Click on each of the stages below for a brief overview of the AWMSG appraisal process

Initial information

Initial information should be submitted by the company for all newly licensed medicines, each new indication and/or formulation and ideally within one month of receipt of positive opinion from the Committee for Medicinal Products for Human Use (CHMP). This information is required by the AWMSG Steering Committee to decide whether a medicine requires appraisal.  

Clinical expert opinion

AWTTC identify clinical experts via the appropriate Welsh Professional Society or Clinical Network or Medicines and Therapeutics Committees. Clinical experts are contacted by AWTTC for advice on current practice in NHS Wales and advice on appropriate comparators before inviting a full (Form B) or limited (Form C) submission.